BioMarin Pharmaceutical has submitted a New Drug Submission (NDS) for Vimizim (elosulfase alfa) under Priority Review status. Vimizim is an investigational enzyme replacement therapy for the treatment of patients with the lysosomal storage disorder Morquio A syndrome, also called Mucopolysaccharidosis Type IVA (MPS IVA). Approval of Vimizim would make it the first available drug treatment option for Canadians who have this rare genetic metabolic disorder. Health Canada designates Priority Revie...